Target
$38.37 → $38.34
Current stock research snapshot · 7/8/26 49 days old
TXG10x Genomics
Investment conviction●●○○○2 of 5 · current snapshot
Research target$38.34Current stock price target
Investment thesis statusINTACTLast reviewed 7/8/26
Market cap$4.76BSnapshot value · 7/8/26
Research history
See all TXG changes ↗What changed
Single-cell + spatial biology platform leader. 10x Chromium is the dominant single-cell platform; Visium/Xenium/Atera for spatial. 15% CAGR spatial biology market driven by oncology.
Atera platform launch (Q1 2026) expanding spatial capabilities; Roche Axelios single-cell/spatial partnership; rising cancer burden (35M+ new cases projected by 2050) driving spatial adoption.
Pre-revenue trajectory — unprofitable, narrative-driven; FFPE compatibility and cost remain adoption limiters; competitive pressure from Bruker/Vizgen/Akoya; single-cell market maturation.
Bullish — $TXG in US momentum top 10 on Aug 25 (RS score high); prior post noted up 50% since shared. [X search Aug 2026]
Snapshot · 7/8/26🟡 Mixed · ins-$4.5M · 13F 12+/13-×0.5 · short↑0.31
Snapshot · 7/8/26